High Prevalence of Hepatitis and Increasing Awareness Regarding Hepatitis to Augment Growth of Hepatitis Drugs Market
High prevalence of hepatitis is expected to propel growth of the global hepatitis drugs market. For instance, in May 2019, according to the study, ‘Prevalence of hepatitis B surface antigen (HBsAg) positivity and its associated factors in Rwanda’, published in May 2019, in BMC Infectious Diseases, the prevalence of hepatitis B surface antigen was 3.9% in the study population. Moreover, development of novel diagnostic tests is also expected to aid in growth of the market. For instance, in January 2019, LabCorp, along with its subsidiary Covance Inc., partnered with GENFIT, a biopharmaceutical company focused on R&D in liver diseases, for access to non-alcoholic steatohepatitis liver diagnostic test for the clinical research market. Increasing awareness regarding hepatitis is expected to offer lucrative growth opportunities for players in the global hepatitis drugs market . For instance, in May 2020, Echosens, a provider of non-invasive diagnostic products and services for li...